Results 121 to 130 of about 31,541 (206)

COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review. [PDF]

BMC Infect Dis
Bosquet A, Affo C, Happe F, Helfer H, Versini E, Mahé I.   +5 more
europepmc   +1 more source

Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement. [PDF]

J Infect Dis
Perazzolo S, Flexner CW, Stephen ZR, Acosta EP, Bender Ignacio RA, Ho RJY.   +5 more
europepmc   +1 more source

Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Pattern Recognition Algorithms in Pharmacogenomics and Drug Repurposing-Case Study: Ribavirin and Lopinavir. [PDF]

Pharmaceuticals (Basel)
Calvo H, Islas-Díaz D, Hernández-Laureano E.   +2 more
europepmc   +1 more source

Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. [PDF]

AIDS
Blankenberger J, Devendra A, Bakaya M, Lee T, Steffy TLF, Makhesi T, Gilbride CJ, Belus JM, Thahane L, Tschumi N, Marake NB, Tarumbiswa T, Huber R, Chammartin F, Labhardt ND, Brown JA.   +15 more
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Cryptococcal Osteomyelitis in a Virally Suppressed Adolescent Living With HIV: A Case Report. [PDF]

Case Rep Infect Dis
Mandikiyana Chirimuta LA, Rambanapasi C, Musorowegomo D, Nyatanga G, Mapfumo A, Chikati EF.   +5 more
europepmc   +1 more source

Central auditory tests reveal deficits in HIV treatment. [PDF]

Front Public Health
Kambhampaty AK, Niemczak CE, Hill RA, Howe CG, Leigh SM, Lichtenstein J, Roth RM, Adhikari M, Zhang L, Fellows AM, Magohe A, Palumbo P, Gui J, Massawe ER, Buckey JC.   +14 more
europepmc   +1 more source

Fisetin as an Antiviral Agent Targeting the RNA-Dependent RNA Polymerase of SARS-CoV-2: Computational Prediction and In Vitro Experimental Validation. [PDF]

Microorganisms
Hernández-Rodríguez X, Lira-Hernández FI, Reyes-Ruíz JM, Osuna-Ramos JF, Farfán-Morales CN, Calderón-Sandate DN, Castañeda-Delgado JE, León-Juárez M, Ángel RMD, Rivas-Santiago B, Noriega S, Cañedo-Figueroa DM, Montaño S, Santos-Mena AO, García-Herrera AC, De Jesús-González LA.   +15 more
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source